<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?>

<feed xmlns="http://purl.org/atom/ns#" version="0.3" xml:lang="en-US">
<link href="https://www.blogger.com/atom/19224571" rel="service.post" title="Hep C Virus" type="application/atom+xml"/>
<link href="https://www.blogger.com/atom/19224571" rel="service.feed" title="Hep C Virus" type="application/atom+xml"/>
<title mode="escaped" type="text/html">Hep C Virus</title>
<tagline mode="escaped" type="text/html">Hep C Virus Information</tagline>
<link href="http://www.about-hepatitis-c.com/hep-c-virus" rel="alternate" title="Hep C Virus" type="text/html"/>
<id>tag:blogger.com,1999:blog-19224571</id>
<modified>2006-04-12T07:16:46Z</modified>
<generator url="http://www.blogger.com/" version="6.72">Blogger</generator>
<info mode="xml" type="text/html">
<div xmlns="http://www.w3.org/1999/xhtml">This is an Atom formatted XML site feed. It is intended to be viewed in a Newsreader or syndicated to another site. Please visit the <a href="http://help.blogger.com/bin/answer.py?answer=697">Blogger Help</a> for more info.</div>
</info>
<convertLineBreaks xmlns="http://www.blogger.com/atom/ns#">true</convertLineBreaks>
<entry xmlns="http://purl.org/atom/ns#">
<link href="https://www.blogger.com/atom/19224571/114482620638256802" rel="service.edit" title="Hep C Virus - Tata Steel goes stronger   " type="application/atom+xml"/>
<author>
<name>Greg</name>
</author>
<issued>2006-04-11T20:15:05-07:00</issued>
<modified>2006-04-12T07:16:46Z</modified>
<created>2006-04-12T07:16:46Z</created>
<link href="http://www.about-hepatitis-c.com/hep-c-virus/2006/04/hep-c-virus-tata-steel-goes-stronger.html" rel="alternate" title="Hep C Virus - Tata Steel goes stronger   " type="text/html"/>
<id>tag:blogger.com,1999:blog-19224571.post-114482620638256802</id>
<title mode="escaped" type="text/html">Hep C Virus - Tata Steel goes stronger   </title>
<content type="application/xhtml+xml" xml:base="http://www.about-hepatitis-c.com/hep-c-virus" xml:space="preserve">
<div xmlns="http://www.w3.org/1999/xhtml">
<div xmlns="http://purl.org/atom/ns#"> <br/>
<a href="http://www.newstodaynet.com/11apr/bu1.htm'" rel="nofollow" target="_blank">Tata Steel goes stronger </a>
<br/> News Today - Apr 11  3:57 AM<br/> Tata Steel finished the year with numerous records and remarkable achievements. Most of the units and facilities under the million tonne expansion project were commissioned during the year. It was indeed challenge to handle so many commissioning in a running plant and yet increase the production.Save to My Web<br/>
<br/>
<a href="http://www.pharmaceutical-business-review.com/article_news.asp?guid=1296964D-64FC-473E-A869-23FB62BB45D7'" rel="nofollow" target="_blank">Schering-Plough and PTC ink hepatitis C deal </a>
<br/> Pharmaceutical Business Review - Mar 21  6:06 PM<br/> Schering-Plough and PTC Therapeutics have entered into an exclusive collaboration and licensing agreement to develop PTCs preclinical compounds for the oral treatment of hepatitis C virus infection and other viral diseases.Save to My Web<br/>
<br/>
<a href="http://biz.yahoo.com/prnews/060404/nytu137.html?.v=47'" rel="nofollow" target="_blank">Benitec CEO Sara Cunningham to Speak at BIO 2006 on RNA Interference Panel </a>
<br/> [Press Release] PR Newswire via Yahoo! Finance - Apr 04  7:33 AM<br/>  Benitec Ltd. , a leading developer of RNA interference -based therapeutics, announced today that Sara Cunningham, Chief Executive Officer of Benitec, will be speaking on a panel entitled "RNAi: Advancing Therapeutic Development" at the BIO 2006 Chicago Annual International Convention.Save to My Web<br/>
<br/>
<a href="http://www.finanznachrichten.de/nachrichten-2006-03/artikel-6210952.asp'" rel="nofollow" target="_blank">ViroPharma Announces Positive Phase 2 Results Demonstrating That Maribavir Significantly Reduces CMV Reactivation </a>
<br/> FinanzNachrichten - Mar 29  5:22 PM<br/> EXTON, Pa., March 29 /PRNewswire-FirstCall/ -- ViroPharma Incorporated ( Nachrichten ) today announced positive preliminary results from a Phase 2 study with maribavir, an oral antiviral drug candidate currently being developed to inhibit cytomegalovirus (CMV) reactivation in transplant patients.Save to My Web  </div>
</div>
</content>
<draft xmlns="http://purl.org/atom-blog/ns#">false</draft>
</entry>
</feed>
